

Allergic Rhinitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight

DelveInsight's Acid Sphingomyelinase Deficiency Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LAS VEGAS, UNITED STATES, March 20, 2024 /EINPresswire.com/ -- Some of the key facts of the Allergic Rhinitis Market Report:

The Allergic Rhinitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

According to DelveInsight's evaluation, the total number of diagnosed prevalent cases of Allergic Rhinitis in the 7MM stood at approximately 89 million in 2022, with the US contributing around 25 million cases. It is expected that these cases will rise in the forecast period from 2023 to 2032.

The number of diagnosed prevalent cases of AR in the US was estimated to reach 28% of all cases in the 7MM in 2022, and it is anticipated that this number will rise during the course of the study period (2019-2032)

The number of diagnosed prevalent instances of AR in 2022 was roughly 6.6 million, 13 million, and 5 million for mild, moderate, and severe cases, respectively. This number is expected to rise during the projected period

In November 2022, Hyloris Pharmaceuticals SA has introduced a novel proprietary formulation, specifically a TRPV1 agonist, administered through intranasal spray for the treatment of idiopathic rhinitis. Idiopathic rhinitis is characterized by an excessive expression of TRPV1 in the nasal mucosa, leading to symptoms such as nasal obstruction, rhinorrhea (commonly known as a runny nose), and/or sneezing.

In June 2022, Revelation Biosciences Inc. has successfully concluded the enrollment and dosing phase of its Phase Ib CLEAR clinical trial, evaluating the safety and effectiveness of intranasal REVTx-99b in treating allergic rhinitis. REVTx-99b is a proprietary intranasal formulation designed to address allergic rhinitis symptoms, including persistent nasal congestion. In a Phase I clinical study, the active ingredient demonstrated the ability to upregulate a protein that competes with the native eotaxin receptor, CCR3. This process helps prevent the recruitment of eosinophils and basophils by eotaxin, ultimately reducing Th2 cell recruitment and mitigating the allergic response.

Key Allergic Rhinitis Companies: Regeneron Pharmaceuticals, Allergy Therapeutics, Immunotek, UCB Pharma, Orexo AB, Hyloris Pharmaceuticals, Revelation Biosciences Inc., Yingu Pharmaceutical, Glenmark Specialty S.A., Pfizer, Oxagen Ltd, Idorsia Pharma, Magna Pharma,

Glenmark Specialty, Bayer, and others

Key Allergic Rhinitis Therapies: REGN5713- 5714-5715, Grass MATA MPL, MG01 + T517, Levocetirizine, BLX-028914, Bencycloquidum, Dupilumab, GSP 301 NS, PF-03654764, OC000459, ACT-129968, STA HIST, GSP 301, Azelastine hydrochloride (BAYR9258), and others

Around 178 million common cases of Allergic Rhinitis in the 7MM and 68 million common cases in the EU4 and the UK were estimated by 2022

Some companies have initiated clinical trials investigating new treatment options, including Regeneron Pharmaceuticals' REGN5713-5714-5715 and Grass MATA by Allergy Therapeutics as the potential therapies lined up for forecast in the 7MM in the DelveInsight therapeutics market model

The Allergic Rhinitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Allergic Rhinitis pipeline products will significantly revolutionize the Allergic Rhinitis market dynamics.

Allergic Rhinitis Overview

An atopic disorder called allergic rhinitis (AR) causes symptoms such as sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. The early phase of the immunological response to inhaled antigens is IgE-mediated, while the late phase is leukotriene-mediated. This activity outlines the diagnosis and management of allergic rhinitis and emphasises the importance of the interprofessional team in enhancing patient care.

To Know in detail about the Allergic Rhinitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Allergic Rhinitis Market Forecast](#)

Allergic Rhinitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Allergic Rhinitis Epidemiology Segmentation:

The Allergic Rhinitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Allergic Rhinitis

Prevalent Cases of Allergic Rhinitis by severity

Gender-specific Prevalence of Allergic Rhinitis

Diagnosed Cases of Episodic and Chronic Allergic Rhinitis

Download the report to understand which factors are driving Allergic Rhinitis epidemiology trends @ [Allergic Rhinitis Epidemiology Forecast](#)

Allergic Rhinitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Allergic Rhinitis market or expected to get launched during the study period. The analysis covers Allergic Rhinitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Allergic Rhinitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Allergic Rhinitis Therapies and Key Companies

REGN5713- 5714-5715: Regeneron Pharmaceuticals

Grass MATA MPL: Allergy Therapeutics

MG01 + T517: Immunotek

Levocetirizine: UCB Pharma

BLX-028914: Orexo AB

Bencycloquidum: Yingu Pharmaceutical

Dupilumab: Regeneron Pharma

GSP 301 NS: Glenmark Specialty S.A.

PF-03654764: Pfizer

OC000459: Oxagen Ltd

ACT-129968: Idorsia Pharma

STAHIST: Magna Pharma

GSP 301: Glenmark Specialty

Azelastine hydrochloride (BAYR9258): Bayer

Allergic Rhinitis Market Strengths

The increasing prevalence of Allergic Rhinitis will augment the overall treatment and management landscape

Allergic Rhinitis Market Opportunities

Beneficial reimbursement policies with severity-based Allergic Rhinitis are expected to accentuate the growth of the treatment market

Scope of the Allergic Rhinitis Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Allergic Rhinitis Companies: Regeneron Pharmaceuticals, Allergy Therapeutics, Immunotek, UCB Pharma, Orexo AB, Hyloris Pharmaceuticals, Revelation Biosciences Inc., Yingu Pharmaceutical, Glenmark Specialty S.A., Pfizer, Oxagen Ltd, Idorsia Pharma, Magna Pharma, Glenmark Specialty, Bayer, and others

Key Allergic Rhinitis Therapies: REGN5713- 5714-5715, Grass MATA MPL, MG01 + T517, Levocetirizine, BLX-028914, Bencycloquidum, Dupilumab, GSP 301 NS, PF-03654764, OC000459, ACT-129968, STA HIST, GSP 301, Azelastine hydrochloride (BAYR9258), and others

Allergic Rhinitis Therapeutic Assessment: Allergic Rhinitis current marketed and Allergic Rhinitis emerging therapies

Allergic Rhinitis Market Dynamics: Allergic Rhinitis market drivers and Allergic Rhinitis market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Allergic Rhinitis Unmet Needs, KOL's views, Analyst's views, Allergic Rhinitis Market Access and Reimbursement

To know more about Allergic Rhinitis companies working in the treatment market, visit @ [Allergic Rhinitis Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Allergic Rhinitis Market Report Introduction
2. Executive Summary for Allergic Rhinitis
3. SWOT analysis of Allergic Rhinitis
4. Allergic Rhinitis Patient Share (%) Overview at a Glance
5. Allergic Rhinitis Market Overview at a Glance
6. Allergic Rhinitis Disease Background and Overview
7. Allergic Rhinitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Allergic Rhinitis
9. Allergic Rhinitis Current Treatment and Medical Practices
10. Allergic Rhinitis Unmet Needs
11. Allergic Rhinitis Emerging Therapies
12. Allergic Rhinitis Market Outlook
13. Country-Wise Allergic Rhinitis Market Analysis (2019–2032)
14. Allergic Rhinitis Market Access and Reimbursement of Therapies
15. Allergic Rhinitis Market Drivers
16. Allergic Rhinitis Market Barriers
17. Allergic Rhinitis Appendix
18. Allergic Rhinitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the

business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+ 1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/697293555>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.